Taiwan Takisawa Technology Co., Ltd. logo

Taiwan Takisawa Technology Co., Ltd. (6609)

Market Closed
11 Aug, 05:30
TWSE TWSE
NT$
38. 95
-0.7
-1.7654%
NT$
- Market Cap
- P/E Ratio
- Div Yield
120,135 Volume
- Eps
NT$ 39.65
Previous Close
Add Transaction
Day Range
38.95 39.85
Year Range
33 55.3
Want to track 6609 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

6609 closed today lower at NT$38.95, a decrease of -1.7654% from yesterday's close, completing a monthly decrease of -2.2585% or -NT$0.9. Over the past 12 months, 6609 stock gained 1.4323%.
6609 pays dividends to its shareholders, with the most recent payment made on Aug 22, 2025. The next estimated payment will be in In 1 weeks on Aug 22, 2026 for a total of NT$0.77.
The last earnings report, released on Mar 12, 2026, missed the consensus estimates by -0.67%. On average, the company has fell short of earnings expectations by -0.67%, based on the last three reports.
Taiwan Takisawa Technology Co., Ltd. has completed 7 stock splits, with the recent split occurring on Aug 24, 2018.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on HKEX (HKD).

6609 Chart

Taiwan Takisawa Technology Co., Ltd. (6609) FAQ

What is the stock price today?

The current price is NT$38.95.

On which exchange is it traded?

Taiwan Takisawa Technology Co., Ltd. is listed on TWSE.

What is its stock symbol?

The ticker symbol is 6609.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Taiwan Takisawa Technology Co., Ltd. ever had a stock split?

Taiwan Takisawa Technology Co., Ltd. had 7 splits and the recent split was on Aug 24, 2018.

Taiwan Takisawa Technology Co., Ltd. Profile

Health Care Equipment & Supplies Industry
Healthcare Sector
Mr. Guohui Wang CEO
TWSE Exchange
TW0006609001 ISIN
China Country
341 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Shanghai HeartCare Medical Technology Corporation Limited is at the forefront of innovation in the field of neuro-interventional medical devices, focused on developing, manufacturing, and selling state-of-the-art products for the medical industry. Founded in 2016 and headquartered in Shanghai, the People's Republic of China, the company specializes in providing advanced solutions for the treatment and prevention of acute ischemic stroke, neurovascular stenosis, and hemorrhagic stroke. Through its dedication to research and development, Shanghai HeartCare Medical Technology Corporation Limited aims to improve patient outcomes and enhance the quality of life for those suffering from these critical conditions.

Products and Services

  • Ischemic Stroke Thrombectomy Devices

    These devices are engineered for the removal of clots from blocked brain arteries to restore blood flow in patients experiencing an acute ischemic stroke. Their innovative design and technology make them an effective solution for emergency stroke treatment.

  • Intracranial Stenosis Treatment

    Shanghai HeartCare provides advanced solutions for the treatment of intracranial arterial stenosis, a condition that leads to narrowed brain arteries, utilizing cutting-edge devices designed to widen the arterial passageways and enhance blood flow, thereby reducing the risk of stroke.

  • Flow Diverter

    The flow diverter device is aimed at treating patients with aneurysms by diverting blood flow away from the aneurysm sac, thus promoting aneurysm thrombosis while maintaining patency of the parent vessel. This minimizes the risk of rupture and subsequent hemorrhagic stroke.

  • Vascular Access Devices

    These devices facilitate access to the vascular system for the purpose of performing diagnostic or therapeutic procedures, including the deployment of stents or removal of blockages, paramount for effective treatment of various neurovascular conditions.

  • Neurovascular Stenosis Treatment

    Focused on combating neurovascular stenosis, the company offers a range of devices that alleviate this condition by widening narrow vascular passages in the brain, ensuring an unimpeded flow of blood, essential for the healthy functioning of brain tissues.

  • Hemorrhagic Stroke Treatment

    Shanghai HeartCare’s offerings in this category are designed to limit the damage caused by hemorrhagic strokes through innovative devices that prevent blood vessel rupture or manage its consequences, thereby saving lives and improving recovery outcomes.

  • Interventional Access

    The interventional access products provide medical professionals with the necessary tools to access areas of the body affected by neurovascular conditions, facilitating a wide range of interventions from diagnostics to treatment application, ensuring high precision and safety.

Contact Information

Address: Building 38
Phone: 86 21 3752 6556